5,6-Dimethoxybenzofuran-3-one derivatives: a novel series of dual Acetylcholinesterase/Butyrylcholinesterase inhibitors bearing benzyl pyridinium moiety
© Nadri et al.; licensee BioMed Central Ltd. 2013
Received: 21 January 2013
Accepted: 15 February 2013
Published: 27 February 2013
Several studies have been focused on design and synthesis of multi-target anti Alzheimer compounds. Utilizing of the dual Acetylcholinesterase/Butyrylcholinesterase inhibitors has gained more interest to treat the Alzheimer’s disease. As a part of a research program to find a novel drug for treating Alzheimer disease, we have previously reported 6-alkoxybenzofuranone derivatives as potent acetylcholinesterase inhibitors. In continuation of our work, we would like to report the synthesis of 5,6-dimethoxy benzofuranone derivatives bearing a benzyl pyridinium moiety as dual Acetylcholinesterase/Butyrylcholinesterase inhibitors.
The synthesis of target compounds was carried out using a conventional method. Bayer-Villiger oxidation of 3,4-dimethoxybenzaldehyde furnished 3,4-dimethoxyphenol. The reaction of 3,4-dimethoxyphenol with chloroacetonitrile followed by treatment with HCl solution and then ring closure yielded the 5,6-dimethoxy benzofuranone. Condensation of the later compound with pyridine-4-carboxaldehyde and subsequent reaction with different benzyl halides afforded target compounds. The biological activity was measured using standard Ellman’s method. Docking studies were performed to get better insight into interaction of compounds with receptor.
The in vitro anti acetylcholinesterase/butyrylcholinesterase activity of compounds revealed that, all of the target compounds have good inhibitory activity against both Acetylcholinesterase/Butyrylcholinesterase enzymes in which compound 5b (IC50 = 52 ± 6.38nM) was the most active compound against acetylcholinesterase. The same binding mode and interactions were observed for the reference drug donepezil and compound 5b in docking study.
In this study, we presented a new series of benzofuranone-based derivatives having pyridinium moiety as potent dual acting Acetylcholinesterase/Butyrylcholinesterase inhibitors.
Alzheimer’s disease (AD) is a progressive and age-dependent neurodegenerative brain disorder that leads to dementia, cognitive impairment, and memory loss [1, 2]. The main cause of Alzheimer’s disease etiology is not completely known however, many diverse factors such as hippocampal acetylcholine (Ach) decrease, β-amyloid (Aβ) aggregation and τ-protein deposits seem to play significant roles in initiation and progression of the disease [3–5]. Based on these findings three hypotheses was established: cholinergic, β-amyloid and tau hypothesis.
Moreover, it has been demonstrated that the inhibition of AChE may lead to an increase in Butyrylcholinesterase (BuChE) activity in the hippocampus that causes hydrolysis of AChE by a new way. Therefore, the maintenance of AChE/BuChE activity ratio in the hippocampus as seen in the healthy brain, could improve the signs and symptoms of AD . As a result, design and synthesis of dual AChE/BuChE inhibitors should be considered to find more potent agents against AD .
Materials and methods
Synthesis of 3,4-dimethoxyphenol (1)
A mixture of m-chloro-peroxybenzoic acid (m-CPBA) (7 g, 32.5 mmol) in the dry dichloromethane (DCM) (40 ml) was prepared at 0°C and vigorously stirred. Then a solution of 3,4-dimethoxybenzaldehyde (5 g, 30 mmol) in the dry DCM (10 ml) was added dropwise during 1 hour. The resulting mixture was kept at room temperature and then refluxed for 16 hours. After cooling, the mixture was washed with aqueous solution of saturated sodium hydrogen carbonate (3 × 20 ml) followed by washing with sodium thiosulfate 10% (25 ml) to neutralize excess amount of m-CPBA. The solvent was then evaporated under reduced pressure and the resulting crude material was dissolved in methanol. The solution was stirred for 4 hours with excess amount of sodium hydroxide 10% solution at room temperature. The pH of solution was adjusted to 1 using HCl 6 N solution. The solution was then extracted with DCM (3 × 25 ml) washed with brine and dried using anhydrous Na2SO4. The solvent was removed to yield brown syrup, which was purified with column chromatography using petroleum ether and ethyl acetate (1:1) as eluent to give compound 1. White brown solid, m.p. 74–78°C, 84% yield .
Synthesis of 2-chloro-1-(2-hydroxy-4,5-dimethoxyphenyl)ethanone (2)
To a mixture of 3,4-dimethoxyphenol (1) (4.93 g, 32 mmol) and chloroacetonitrile (2.4 g, 32 mmol) in dry ether (150 ml) was added anhydrous ZnCl2 (1.44 g, 10.6 mmol). The mixture was cooled to 0°C and HCl gas was bubbled through the reaction for 2.5 hours. The mixture was left in the room temperature overnight and then cooled to 0°C. The precipitated iminium was filtered off and washed three times with ether. The imine was dissolved in 160 ml of 1 N HCl and refluxed for 90 min. The resulting mixture was extracted with DCM (3 × 100 ml) and the solvent was removed under reduced pressure to give 2.88 g white brown solid 40% yield (no further purification was needed).
Synthesis of 5,6-dimethoxybenzofuran-3(2H)-one (3)
The crude extract of 2-chloro-1-(2-hydroxy-4,5-dime-thoxyphenyl)ethanone (2) (1.15 g, 5 mmol) was dissolved in 10 ml ethanol and then refluxed for 10 min under argon. Sodium acetate trihydrate (700 mg) was added thereto and refluxed for 10 min again. The resulting mixture was cooled immediately and then filtered off. The solvent was evaporated and compound 3 was yielded by re-crystallization from ethanol. White needle crystals, m.p. 163–165, 470 mg, 48%. IR νmax/cm-1 (KBr) : 1708 (C = O), 1H NMR (CDCl3, 80 MHz), 7.02 (s, 1H, H4-aromatic) 6.59 (s, 1H, H7-aromatic) 4.61 (s, 2H, H2-aliphatic) 3.97 (s, 3H, -OCH3) 3.87 (s, 3H, -OCH3), EI-MS m/z (%) 194 (M+, 100), 165 (45), 135 (88), 34 (57).
Synthesis of (Z)-5,6-dimethoxy-2-(pyridin-4-ylmethylene)benzofuran-3(2H)-one (4)
5,6-dimethoxybenzofuran-3(2H)-one 3 (388 mg, 2 mmol), pyridine-4-carbaldehyde (308 mg, 2.88 mmol) and PTSA (548 mg, 3.18 mmol) were suspended in the dry toluene (25 ml) and refluxed using Dean-Stark apparatus for 2 hours. After cooling the resulting mixture, the precipitated solid was filtered off. The wet solid was suspended in aqueous 10% NaHCO3 solution (50 ml) and stirred for 60 minutes at room temperature. The filtered resulting solid was washed with water (50 ml) and then air dried. The crude solid was purified by re-crystallization from acetonitrile to yield compound 4. 400 mg, 70% yield, m.p. 265–268°C, IR νmax/cm-1 (KBr) : 1705 (C = O), 1635 (C = C alkene), 1H NMR (CDCl3, 80 MHz), 8.69 (dd, 2H, Ha-pyridine, J = 4.5 Hz, J = 2 Hz), 7.70 (dd, 2H, Hb-pyridine, J = 5 Hz, J = 1.5 Hz), 7.17 (s, 1H, H4), 6.83 (s, 1H, H7), 6.69 (s, 1H, Hvinylic), 4.03 (s, 3H, -OCH3), 3.91 (s, 3H, -OCH3), EI-MS m/z (%) 284 ( (M+ + 1), 100), 224 (90), 33 (65).
General procedure for the synthesis of 1-benzyl-4-((5,6-dimethoxy-3-oxobenzofuran-2(3H)-ylidene)methyl) pyridinium halide derivatives (5a-g)
(Z)-5,6-Dimethoxy-2-(pyridin-4-ylmethylene) benzofuran-3(2H)-one (4) (1 equiv.), was suspended in 7 ml dry acetonitrile and heated under reflux condition. Afterwards different substituted benzyl halides (1.2 equiv.) were added thereto. The mixture was refluxed for 2–3 hours followed by cooling to room temperature. After that the solvent was evaporated and 15 ml n-hexane was added to the residue. The resulting mixture was filtered off and the precipitated crystals were separated, washed with n-hexane and dried. Flash chromatography of the crystals using the chloroform-methanol (99–1) as the mobile phase, furnished the final compounds 5a-g.
(Z)-1-Benzyl-4-((5,6-dimethoxy-3-oxobenzofuran-2(3H)-ylidene) methyl) pyridinium bromide (5a)
Starting from (Z)-5,6-dimethoxy-2-(pyridin-4-ylmethylene)benzofuran-3(2H)-one (1 mmol, 0.283 g) and benzyl bromide (1.2 mmol, 0.205 g), compound 5a was obtained, quantitative yield, mp over 300°C, IR νmax/cm-1 (KBr) : 1689 (C = O), 1607 (C = C alkene), 1H NMR (DMSO-d6, 500 MHz), 9.20 (d, 2H, Ha-Pyridine, J = 6.7 Hz), 8.51 (d, 2H, Hb-pyridine, J = 6.7 Hz), 7.55-7.46 (m, 5H, Hphenyl), 7.27 (s, 1H, H4-benzofuranone), 7.25 (s, 1H, H7-benzofuranone), 7.04 (s, 1H, Hvinylic), 5.85 (s, 2H, Hbenzylic), 3.98 (s, 3H, -OCH3), 3.83(s, 3H, -OCH3), EI-MS m/z (%) 283 (10), 91 (100), 77 (15), 43 (38), Anal. Calcd.for C23H20BrNO4: C, 60.81; H, 4.44; N, 3.08 Found: C, 60.68; H, 4.72; N, 3.24.
(Z)-1-(4-Fluorobenzyl)-4-((5,6-dimethoxy-3-oxobenzofuran-2(3H)-ylidene) methyl) pyridinium bromide (5b)
Starting from (Z)-5,6-dimethoxy-2-(pyridin-4-ylmethylene)benzofuran-3(2H)-one (1 mmol, 0.283 g) and 4-fluoro-benzyl bromide (1.2 mmol, 0.226 g), compound 5b was obtained, quantitative yield, mp 276–279°C, IR νmax/cm-1 (KBr) : 1687 (C = O), 1608 (C = C alkene), 1H NMR (DMSO-d6, 500 MHz), 9.22 (d, 2H, Ha-pyridine, J = 6.7 Hz), 8.52 (d, 2H, Hb-pyridine, J = 6.75 Hz), 7.67-7.64 (m, 2H, Hphenyl), 7.32-7.28 (m, 2H, Hphenyl), 7.25 (s, 1H, H4-benzofuranone), 7.23 (s, 1H, H7-benzofuranone), 7.04 (s, 1H, Hvinylic), 5.86 (s, 2H, Hbenzylic), 3.97 (s, 3H, -OCH3), 3.82(s, 3H, -OCH3), EI-MS m/z (%) 283 (12), 109 (100), 95 (18), 43 (40), Anal. Calcd.for C23H19BrFNO4: C, 58.49; H, 4.05; N, 2.97 Found: C, 58.85; H, 4.17; N, 2.74.
(Z)-1-(3-Methylbenzyl)-4-((5,6-dimethoxy-3-oxobenzofuran-2(3H)-ylidene) methyl) pyridinium chloride (5c)
Starting from (Z)-5,6-dimethoxy-2-(pyridin-4-ylmethylene)benzofuran-3(2H)-one (1 mmol, 0.283 g) and 3-methyl-benzyl chloride (1.2 mmol, 0.169 g), compound 5c was obtained, quantitative yield, mp 293–295°C, IR νmax/cm-1 (KBr) : 1694 (C = O), 1605 (C = C alkene), 1H NMR (DMSO-d6, 500 MHz), 9.25 (d, 2H, Ha-pyridine, J = 6.4 Hz), 8.51 (d, 2H, Hb-pyridine, J = 6.45 Hz), 7.48-7.41 (m, 3H, Hphenyl), 7.33 (s, 1H, Hphenyl), 7.26 (s, 1H, H4-benzofuranone), 7.24 (s, 1H, H7-benzofuranone), 7.03 (s, 1H, Hvinylic), 5.83 (s, 2H, Hbenzylic), 3.94 (s, 3H, –OCH3), 3.80 (s, 3H, –OCH3), 2.3 (s, 3H, H –CH3phenyl), EI-MS m/z (%) 283 (12), 105 (100), 91 (16), 43 (38), Anal. Calcd.for C24H22ClNO4: C, 68.00; H, 5.23; N, 3.30 Found: C, 68.34; H, 5.05; N, 3.42.
(Z)-1-(2-Fluorobenzyl)-4-((5,6-dimethoxy-3-oxobenzofuran-2(3H)-ylidene) methyl) pyridinium chloride (5d)
Starting from (Z)-5,6-dimethoxy-2-(pyridin-4-ylmethylene)benzofuran-3(2H)-one (1 mmol, 0.283 g) and 2-fluorobenzyl chloride (1.2 mmol, 0.173 g), compound 5d was obtained, quantitative yield, mp over 300°C, IR νmax/cm-1 (KBr) : 1701 (C = O), 1608 (C = C alkene), 1H NMR (DMSO-d6, 500 MHz), 9.19 (d, 2H, Ha-pyridine, J = 5.8 Hz), 8.53 (d, 2H, Hb-pyridine, J = 5.95 Hz), 7.65-7.62 (m, 1H, Hphenyl), 7.54-7.52 (m, 1H, Hphenyl), 7.34-7.31 (m, 2H, Hphenyl), 7.26 (s, 1H, H4-benzofuranone), 7.23 (s, 1H, H7-benzofuranone), 7.05 (s, 1H, Hvinylic), 5.94 (s, 2H, Hbenzylic), 3.95 (s, 3H, –OCH3), 3.80 (s, 3H, –OCH3), EI-MS m/z (%) 283 (16), 109 (100), 95 (18), 43 (35), Anal. Calcd.for C24H22ClNO4: C, 68.00; H, 5.23; N, 3.30 Found: C, 68.12; H, 5.32; N, 3.37.
(Z)-1-(3-Fluorobenzyl)-4-((5,6-dimethoxy-3-oxobenzofuran-2(3H)-ylidene) methyl) pyridinium chloride (5e)
Starting from (Z)-5,6-dimethoxy-2-(pyridin-4-ylmethylene) benzofuran-3(2H)-one (1 mmol, 0.283 g) and 3-fluorobenzyl chloride (1.2 mmol, 0.173 g), compound 5e was obtained, quantitative yield, mp 291–294°C, IR νmax/cm-1 (KBr) : 1690 (C = O), 1611 (C = C alkene), 1H NMR (DMSO-d6, 500 MHz), 9.29 (d, 2H, Ha-pyridine, J = 6 Hz), 8.52 (d, 2H, Hb-pyridine, J = 6.2 Hz), 7.51-7.50 (m, 2H, Hphenyl), 7.43-7.41 (m, 1H, Hphenyl), 7.30-7.27 (m, 1H, Hphenyl), 7.26 (s, 1H, H4-benzofuranone), 7.23 (s, 1H, H7-benzofuranone), 7.04 (s, 1H, Hvinylic), 5.9 (s, 2H, Hbenzylic), 3.95 (s, 3H, –OCH3), 3.8 (s, 3H, –OCH3), EI-MS m/z (%) EI-MS m/z (%) 283 (19), 109 (100), 95 (15), 43 (32), Anal.Calcd.for C23H19ClFNO4: C, 64.57; H, 4.48; N, 3.27 Found: C, 64.72; H, 4.23; N, 3.16.
(Z)-1-(2-Methylbenzyl)-4-((5,6-dimethoxy-3-oxobenzofuran-2(3H)-ylidene) methyl) pyridinium chloride (5f)
Starting from (Z)-5,6-dimethoxy-2-(pyridin-4-ylmethylene)benzofuran-3(2H)-one (1 mmol, 0.283 g) and 2-methyl-benzyl chloride (1.2 mmol, 0.169 g), compound 5f was obtained, quantitative yield, mp 287–290°C, IR νmax/cm-1 (KBr) : 1692 (C = O), 1607(C = C alkene), 1H NMR (DMSO-d6, 500 MHz), 9.08 (d, 2H, Ha-pyridine, J = 6.85 Hz), 8.52 (d, 2H, Hb-pyridine, J = 6.8 Hz), 7.81- 7.78 (m, 1H, Hphenyl), 7.45-7.38 (m, 1H, Hphenyl), 7.32-7.30 (m, 2H, Hphenyl), 7.29 (s, 1H, H4-benzofuranone), 7.24 (s, 1H, H7-benzofuranone), 6.99 (s, 1H, Hvinylic), 5.88 (s, 2H, Hbenzylic), 3.99 (s, 3H, –OCH3), 3.84 (s, 3H, –OCH3), 2.35 (s, 3H, H CH3phenyl) EI-MS m/z (%) 283 (21), 105 (100), 91 (18), 43 (40), Anal. Calcd.for C24H22ClNO4: C, 68.00; H, 5.23; N, 3.30 Found: C, 68.26; H, 5.15; N, 3.25.
(Z)-1-(4-Methylbenzyl)-4-((5,6-dimethoxy-3-oxobenzofuran-2(3H)-ylidene) methyl) pyridinium chloride (5g)
Starting from (Z)-5,6-dimethoxy-2-(pyridin-4-ylmethylene)benzofuran-3(2H)-one (1 mmol, 0.283 g) and 4-methylbenzyl chloride (1.2 mmol, 0.169 g), compound 5g was obtained, quantitative yield, mp 294–297°C, IR νmax/cm-1 (KBr) : 1690 (C = O), 1606 (C = C alkene), 1H NMR (DMSO-d6, 500 MHz), 9.24 (d, 2H, Ha-pyridine, J = 6.4 Hz), 8.49 (d, 2H, Hb-pyridine, J = 6.5 Hz), 7.47 (d, 2H, J = 6.3 Hz, Hphenyl), 7.26 (d, 2H, J = 6.4 Hz, Hphenyl), 7.20 (s, 1H, H4-benzofuranone), 7.17 (s, 1H, H7-benzofuranone), 6.96 (s, 1H, Hvinylic), 5.80 (s, 2H, Hbenzylic), 3.95 (s, 3H, –OCH3), 380 (s, 3H, –OCH3), 2.28 (s, 3H, H –CH3phenyl), EI-MS m/z (%) 283 (17), 105 (100), 91 (22), 43 (31), Anal. Calcd.for C24H22ClNO4: C, 68.00; H, 5.23; N, 3.30 Found: C, 67.76; H, 5.38; N, 3.19.
AChE (AChE, E.C. 184.108.40.206, Type V-S, lyophilized powder, from electric eel, 1000 unit), Cholinesterase from equine serum were purchased from Sigma–Aldrich (Steinheim, Germany). DTNB (5, 5′-Dithiobis-(2-nitrobenzoic acid)), KH2PO4, K2HPO4, KOH, NaHCO3, BTChI (butyrylthio-choline iodide) and ATChI (acetylthiocholine iodide) were obtained from Fluka (Buchs, Switzerland). To afford an assay concentration range (10-4 to 10-9 M), the tested compounds were dissolved in a mixture of 20 ml distilled water and 5 ml methanol followed by dilution in 0.1 M KH2PO4/K2HPO4 buffer (pH 8.0) to obtain final concentration.
The colorimetric Ellman’s method was applied to evaluate anti AChE/BuChE activity of tested compounds. The solutions temperature was adjusted to 25°C prior to use. Five different concentrations of each compound were tested to obtain 20% to 80% inhibition of AChE and/or BuChE activity. The assay medium contained 3 ml of 0.1 M phosphate buffer pH 8.0, 100 μl of 0.01 M 5, 5′-dithio-bis(2-nitrobenzoic acid), 100 μl of 2.5 unit/mL enzyme solution (AChE, E.C. 220.127.116.11, Type V-S, lyophilized powder, from electric eel or BuChE from equine serum).
Then 100 μl of each tested compounds, were added to the assay medium and pre-incubated at 25°C for 15 min followed by adding 20 μl of substrate (acetylthiocholine iodide or butyrylthiocholine iodide). After that the rate of absorbance change was measured at 412 nm for 2 minutes. The blank reading solution was used to justify non-enzymatic hydrolysis of substrate during the assay. The blank solution contained 3 ml buffer, 200 μl water, 100 μl DTNB and 20 μl substrate. As a reference, an identical solution of the enzyme without the inhibitor is processed following the same protocol. The rate of the substrate enzymatic hydrolysis was calculated, and % inhibition of the tested compounds was calculated. Each concentration was evaluated in triplicate, and the IC50 values were determined from inhibition curves (% of inhibition versus log inhibitor’s concentration) graphically. Kapková et al. reported more details of the procedure [16, 17].
Docking simulation studies were done using Autodock Vina 1.1.1 . For this purpose, the pdb structure of acetylcholinesterase (1EVE) was retrieved from the Brookhaven protein database (RCSB)(http://www.rcsb.org) as a complex bound with inhibitor Donepezil. Subsequently, all water molecules and the co-crystallized ligand were removed from the pdb structure. Afterward the polar hydrogens were added to the receptor and pdbqt format of the receptor was created using Autodock Tools 1.5.4 .The ligand coordinates were generated using Marvine-Sketch 5.8.3, 2012, ChemAxon (http://www.chemaxon.com). Then the structures were converted to pdbqt using Open babel 2.3.1 . The docking site was defined by establishing a box at geometrical center of the native ligand present in the above mentioned PDB structure with the dimensions of 40, 40, and 40. The exhaustiveness parameter was set to 80 and the box center was set to the dimensions of x = 2.023, y = 63.295, z = 67.062. Finally, the lowest energy conformations between the AChE and inhibitor were selected for analyzing the interactions. The results were visualized using Chimera 1.6 .
Results and discussion
The new series of 5,6-dimethoxybenzofuranone derivatives bearing the benzyl pyridinium moiety was evaluated for AChE/BuChE activity using slightly modified Ellman’s protocol.
The type and position of substituents on benzyl moiety could alter the electronic and steric properties of the phenyl ring. Therefore, the affinity of the target compounds toward the enzyme could be modified by changing the substituent on benzyl moiety.
AChE/BuChE inhibitory activity of compounds 5a-g compared with Donepezil hydrochloride (IC 50 = Mean ± SD)
AChE (IC50 ± SD)a(nM)
BuChE (IC50 ± SD)a(nM)
Selectivity for AChEb(S.I)
86 ± 10.94
1400 ± 85
52 ± 6.38
1620 ± 73
115 ± 15.56
740 ± 23
74 ± 11.32
960 ± 41
262 ± 27.49
3620 ± 84
208 ± 31.72
5310 ± 115
514 ± 29.53
7600 ± 260
31 ± 5.12
5400 ± 95
According to the data, all of the synthesized compounds have shown considerable anti AChE/BuChE activity however, did not reach the inhibition level of the reference compound (Donepezil hydrochloride IC50 = 31 ± 5.12 nM).
As already shown in our previous study, the substitution on phenyl ring with small electron withdrawing group such as fluorine atom makes the compounds more active rather than their unsubstituted counterparts. In an opposite way the methyl phenyl substituted compounds proved to be less active than the unsubstituted compounds. In this study using the identical substitution on the ring, the anti cholinesterase activity of 5,6-dimethoxy-benzofuranone derivatives has changed in the same way. Regardless of the substitution on phenyl ring, the activity of more polar 5,6-dimethoxybenzofuranone derivatives were slightly diminished, compared to 6-alkoxy benzofuranone derivatives that were previously reported .
As anticipated, the compound 5b (IC50 = 52 ± 6.38 nM) containing 2-F substituent exhibited the highest inhibitory activity toward the enzyme. However, its activity was less than its counterparts bearing 6-methoxy (IC50 = 10 ± 6.87 nM), 6-ethoxy (IC50 = 32 ± 7.75 nM) and 6-propoxy (IC50 = 50 ± 9.86) on benzofuranone.
Similarly, the 3 and 4-flouro phenyl compounds have shown lower activity in respect to corresponding 6-alkoxy benzofuranone series.
According to Table 1, changing the ortho position of fluorine to either meta or para decreased the activity as in compound (5c) with significantly diminished activity (IC50 = 115 ± 15.56).
Accordingly, methyl substituted compounds have exhibited the order of activity as follow: 5f > 5e > 5g. Insertion of methyl group on phenyl ring in any position reduced the activity in comparison with unsubstituted compound (5a).
In an accord to these findings, it was concluded that substitution on position 3 with F and position 4 with –CH3 was not tolerated.
Docking simulation study
In this study, we presented new benzofuranone-based derivatives of the pyridinium type. The inhibitory activity of new synthesized compounds were tested toward AChE using slightly modified Ellman’s method and compared to those of other derivatives of this class synthesized earlier by our research group. Regarding the biological data, it was revealed that all tested compounds inhibited the AChE in nanomolar range concentration, in which compound 5b, was the most potent compound against AChE. Furthermore a same binding mode and interactions was observed for the reference drug Donepzil and compound 5b in docking study.
In conclusion, 5,6-dimethoxybenzofurane derivatives containing methylbenzyl substituent on pyridine ring demonstrated to be more potent than their corresponding 6-ethoxy and 6-propoxy benzofuranone derivatives .
Molecular graphics and analyses were performed with the UCSF Chimera package. Chimera is developed by the 25 Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco.
- Kung HF, Lee CW, Zhuang ZP, Kung MP, Hou C, Plossl K: Novel stilbenes as probes for amyloid plaques. J Am Chem Soc. 2001, 123: 12740-12741. 10.1021/ja0167147.View ArticlePubMedGoogle Scholar
- Forstl H, Kurz A: Clinical features of Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci. 1999, 249: 288-290. 10.1007/s004060050101.View ArticlePubMedGoogle Scholar
- Fernandez-Bachiller MI, Perez C, Campillo NE, Paez JA, Gonzalez-Munoz GC, Usan P, Garcia-Palomero E, Lopez MG, Villarroya M, Garcia AG, Martinez A, Rodriguez-Franco MI: Tacrine-melatonin hybrids as multifunctional agents for Alzheimer's disease, with cholinergic, antioxidant, and neuroprotective properties. ChemMedChem. 2009, 4: 828-841. 10.1002/cmdc.200800414.View ArticlePubMedGoogle Scholar
- Yankner BA, Dawes LR, Fisher S, Villa-Komaroff L, Oster-Granite ML, Neve RL: Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science. 1989, 245: 417-420. 10.1126/science.2474201.View ArticlePubMedGoogle Scholar
- Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K: Amyloid plaque core protein in Alzheimer's disease and Down syndrome. Proc Natl Acad Sci U S A. 1985, 82: 4245-4249. 10.1073/pnas.82.12.4245.PubMed CentralView ArticlePubMedGoogle Scholar
- Bartus RT, Dean RL, Beer B, Lippa AS: The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982, 217: 408-414. 10.1126/science.7046051.View ArticlePubMedGoogle Scholar
- Richman DP, Agius MA: Treatment of autoimmune myasthenia gravis. Neurology. 2003, 61: 1652-1661. 10.1212/01.WNL.0000098887.24618.A0.View ArticlePubMedGoogle Scholar
- Repantis D, Laisney O, Heuser I: Acetylcholinesterase inhibitors and memantine for neuroenhancement in healthy individuals: a systematic review. Pharmacol Res. 2010, 61: 473-481. 10.1016/j.phrs.2010.02.009.View ArticlePubMedGoogle Scholar
- Karlsson D, Fallarero A, Brunhofer G, Mayer C, Prakash O, Mohan CG, Vuorela P, Erker T: The exploration of thienothiazines as selective butyrylcholinesterase inhibitors. Eur J Pharm Sci. 2012, 47: 190-205. 10.1016/j.ejps.2012.05.014.View ArticlePubMedGoogle Scholar
- Musial A, Bajda M, Malawska B: Recent developments in cholinesterases inhibitors for Alzheimer's disease treatment. Curr Med Chem. 2007, 14: 2654-2679. 10.2174/092986707782023217.View ArticlePubMedGoogle Scholar
- Nadri H, Pirali-Hamedani M, Shekarchi M, Abdollahi M, Sheibani V, Amanlou M, Shafiee A, Foroumadi A: Design, synthesis and anticholinesterase activity of a novel series of 1-benzyl-4-((6-alkoxy-3-oxobenzofuran-2(3H)-ylidene) methyl) pyridinium derivatives. Bioorg Med Chem. 2010, 18: 6360-6366. 10.1016/j.bmc.2010.07.012.View ArticlePubMedGoogle Scholar
- Sheng R, Lin X, Zhang J, Chol KS, Huang W, Yang B, He Q, Hu Y: Design, synthesis and evaluation of flavonoid derivatives as potent AChE inhibitors. Bioorg Med Chem. 2009, 17: 6692-6698. 10.1016/j.bmc.2009.07.072.View ArticlePubMedGoogle Scholar
- Sheng R, Xu Y, Hu C, Zhang J, Lin X, Li J, Yang B, He Q, Hu Y: Design, synthesis and AChE inhibitory activity of indanone and aurone derivatives. Eur J Med Chem. 2009, 44: 7-17. 10.1016/j.ejmech.2008.03.003.View ArticlePubMedGoogle Scholar
- Ellman GL, Courtney KD, Andres V, Feather-Stone RM: A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol. 1961, 7: 88-95. 10.1016/0006-2952(61)90145-9.View ArticlePubMedGoogle Scholar
- Li CC, Xie ZX, Zhang YD, Chen JH, Yang Z: Total synthesis of wedelolactone. J Org Chem. 2003, 68: 8500-8504. 10.1021/jo030228f.View ArticlePubMedGoogle Scholar
- Kapkova P, Alptuzun V, Frey P, Erciyas E, Holzgrabe U: Search for dual function inhibitors for Alzheimer's disease: synthesis and biological activity of acetylcholinesterase inhibitors of pyridinium-type and their Abeta fibril formation inhibition capacity. Bioorg Med Chem. 2006, 14: 472-478. 10.1016/j.bmc.2005.08.034.View ArticlePubMedGoogle Scholar
- Alptuzun V, Kapkova P, Baumann K, Erciyas E, Holzgrabe U: Synthesis and biological activity of pyridinium-type acetylcholinesterase inhibitors. J Pharm Pharmacol. 2003, 55: 1397-1404. 10.1211/0022357021855.View ArticlePubMedGoogle Scholar
- Trott O, Olson AJ: AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010, 31: 455-461.PubMed CentralPubMedGoogle Scholar
- Sanner MF: Python: a programming language for software integration and development. J Mol Graph Model. 1999, 17: 57-61.PubMedGoogle Scholar
- O'Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR: Open Babel: an open chemical toolbox. J Cheminform. 2011, 3: 33-10.1186/1758-2946-3-33.PubMed CentralView ArticlePubMedGoogle Scholar
- Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE: UCSF Chimera–a visualization system for exploratory research and analysis. J Comput Chem. 2004, 25: 1605-1612. 10.1002/jcc.20084.View ArticlePubMedGoogle Scholar
- Lee CY, Chew EH, Go ML: Functionalized aurones as inducers of NAD(P)H:quinone oxidoreductase 1 that activate AhR/XRE and Nrf2/ARE signaling pathways: synthesis, evaluation and SAR. Eur J Med Chem. 2010, 45: 2957-2971. 10.1016/j.ejmech.2010.03.023.View ArticlePubMedGoogle Scholar
- Sugimoto H, Iimura Y, Yamanishi Y, Yamatsu K: Synthesis and structure-activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine hydrochloride and related compounds. J Med Chem. 1995, 38: 4821-4829. 10.1021/jm00024a009.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.